FDA Approves Novo Nordisk's NovoLog
NovoLog® is a rapid-acting insulin analog.
It is called a insulin analog because the chemical components of insulin have been slightly modified, which helps the insulin work faster. NovoLog® is similar to the natural insulin that the body makes after meals in people without diabetes (this is called natural or physiologic action).
NovoLog® works faster at mealtime than regular human insulin, so you may take it and then eat within 5 to 10 minutes. With regular human insulin, you have to wait 30 minutes before you eat.
NovoLog® (insulin aspart) is a rapid-acting human insulin analog sold by Novo Nordisk. NovoLog starts to work almost immediately, compared to Regular insulin which requires about 30 minutes to begin to work. Thus NovoLog can be injected right before a meal, or even immediately after a meal. For parents of children with diabetes who are picky or unpredictable eaters, NovoLog might be just the tool to help match the insulin given to the food eaten.
In addition to working faster, NovoLog has a shorter duration of action than Regular insulin. This means that people who use NovoLog might experience fewer night-time low blood sugars, and need to eat less for their mid-morning and mid-afternoon snacks. It also means that people who use NovoLog might need to increase their long-acting insulin (NPH or Ultralente for example) a little to compensate for the absence of the trailing action of Regular insulin.
NovoLog is a prescription medication used to control blood sugar levels in people with type 1 and type 2 diabetes. The rapid-acting insulin, which is injected 5 to 10 minutes before you start eating, is designed to help control the blood sugar spike that occurs after meals. Potential side effects of NovoLog include injection site skin reactions and low blood sugar levels.
Traditional regular human insulin requires people to inject their insulin dosage 30 minutes before eating. NovoLog has faster absorption, faster onset of action and shorter duration of action than regular human insulin. The quick onset of blood sugar lowering after injection of NovoLog allows people with diabetes to inject themselves immediately before eating, offering flexibility to patients.